Cambium Bio Ltd. Stock Analysis CMB.AX

Cambium Bio Ltd. engages in the development and commercialization of regenerative therapies derived from novel processed human platelets. The firm's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The Company’s lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. The company contains enriched levels of regenerative factors, protease inhibitors, minerals and vitamins. In addition, the Company's stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. The company is also developing Sygenus, a preclinical secretome-based biologic for wound healing.